Noxopharm intends to develop NOX66 as a standard of care drug for use in most forms of cancer where the development of drug-resistance presents limited treatment options for many cancer patients.

The Company's first objectives are (a) conducting a Phase 1a/1b clinical study, and potentially a Phase 2a clinical study depending on the outcome of the Phase 1a/1b clinical study and, (b) to undertake research and development (R&D) programs.

It is anticipated that NOX will list on the ASX during July 2016.